NEXSEN LIMITED (ASX: NXN)
Health care · News and insights
Price unavailable
Latest NXN announcements
Announcement Insights
Nexsen Reworks StrepSure While Advancing RenalSure Toward 2027 FDA Filing
Nexsen’s diagnostics pipeline is advancing on separate tracks: StrepSure’s clinical study was suspended after the company identified changes to improve the test, while RenalSure is progressing toward a targeted mid-2027 US FDA submission, subject to development and clinical validation. In November, Nexsen secured ISO 13485 certification intended to support StrepSure regulatory submissions and commercial supply, and began a feasibility study for a complementary kidney-test cartridge with GENSPEED. The company also added clinical and hospital expertise to its advisory board to support development and validation.
Updated 16 Nov 2026, 09:50 AM Sydney time
Sources
Nexsen Appointments to Advisory BoardResults of MeetingNexsen advances kidney diagnostics programISO 13485 Certification brings StrepSure closer to marketCo Secretary Appoint/Resign and Change of Registered AddressQuarterly Report - Q1 FY27Comments
2026-11-16 · Health care
NXN: $0.150 -3.23% · MC: $32M
Nexsen has appointed Gleneagles Hospital Hong Kong CEO Kenneth Tsang as Advisory Board chair and intensive-care kidney injury expert Professor Kwok-ming Ho as a member. The company says the appointments are intended to support development and clinical validation of its diagnostics, including RenalSure, which is targeting a US FDA submission in mid-2027.
Updated 2026-11-16 09:37
Sources
Nexsen Appointments to Advisory BoardComments
2026-11-09 · Health care
NXN: $0.160 -3.03% · MC: $32M
Nexsen shareholders passed all resolutions at the annual meeting, including approval for additional placement capacity and incentive options for director Shekhar Kumta and Hong Kong employees. The meeting also elected Shekhar Kumta and Grant Pestell as directors.
Updated 2026-11-09 18:13
Sources
Results of MeetingComments
2026-11-06 · Health care
NXN: $0.165 +3.13% · MC: $32M
Nexsen says its RenalSure kidney test is progressing towards a targeted US FDA submission in mid-2027, subject to development and clinical validation. It has also begun a feasibility study with GENSPEED on a complementary cartridge-based test, intended to broaden its offering for hospital monitoring; the company cites a global acute kidney injury diagnostics market forecast to grow from about US$1 billion to about US$2 billion by 2033.
Updated 2026-11-06 09:52
Sources
Nexsen advances kidney diagnostics programComments
2026-11-02 · Health care
NXN: $0.160 +0.00% · MC: $32M
Nexsen Limited (ASX: NXN) has secured ISO 13485 certification covering StrepSure’s design, development and manufacture, establishing a certified quality system intended to support regulatory submissions and commercial supply. The certification advances the product toward an Asia-Pacific launch and FDA submission, and the company says the quality framework can also support other diagnostics in its pipeline. Nexsen also appointed Amanda Burgess as company secretary and changed its registered office.
Updated 2026-11-02 17:16
Sources
ISO 13485 Certification brings StrepSure closer to marketCo Secretary Appoint/Resign and Change of Registered AddressComments
2026-10-28 · Health care
NXN: $0.160 -3.03% · MC: $32M
Nexsen signed a non-binding term sheet for a proposed 50:50 joint venture with FlashDx to develop and commercialise an enhanced GBS test, complementing its StrepSure program for different clinical settings. The company says it has identified changes intended to improve StrepSure ahead of a US regulatory submission, after suspending enrolment in its clinical study and ending assessment of the test in its current form; it reported no adverse safety signal or event. Nexsen also established a Hong Kong research base and added traumatic brain injury and neonatal sepsis programs to its diagnostics pipeline.
Updated 2026-10-28 11:56
Sources
Quarterly Report - Q1 FY27Comments
Comments